United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group Workshop--'Clinical endpoints in trials of biological agents'.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D003603:Cytotoxins / Q000627:therapeutic use; D017277:Drug Approval; D004992:Ethics, Medical; D006801:Humans; D007155:Immunologic Factors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D006113:United Kingdom
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016207:Cytokines; D003603:Cytotoxins; D007155:Immunologic Factors